Entering text into the input field will update the search result below

Flexion Therapeutics (FLXN) CEO Mike Clayman on Q4 2017 Results - Earnings Call Transcript

Mar. 09, 2018 5:12 AM ETPacira BioSciences, Inc. (PCRX)
SA Transcripts profile picture
SA Transcripts

Flexion Therapeutics, Inc. (FLXN) Q4 2017 Earnings Conference Call March 8, 2018 4:30 PM ET


Mike Clayman - Chief Executive Officer

Dan Deardorf - Senior Vice President of Commercial Operations

Scott Young - Vice President for Corporate Communications, Investor Relations


David Maris - Wells Fargo

Dan Busby - RBC Capital Markets

Gary Nachman - BMO Capital

Elliot Wilbur - Raymond James

Serge Belanger - Needham & Co

Frank Brisebois - Laidlaw

Carl Byrnes - Northland Securities

Bruce Jackson - Lake Street Capital

Eric Donaldson - Berenberg


Good afternoon ladies and gentlemen and welcome to the Flexion Therapeutics Q4 and Full Year 2017 Financial Results Conference Call. My name is Bruce and I will be your coordinator today. At this time all participants are in listen-only mode. We will be facilitating a question-and-answer session at the end of today’s call. [Operator Instructions].

I will now turn the call over to the company.

Scott Young

Thank you, Bruce. Good afternoon. This is Scott Young, Vice President for Corporate Communications and Investor Relations. Both the earnings release we issued this afternoon and an archive of this conference call can be found on the company's website at flexiontherapeutics.com. Today’s call will be led by Flexion’s Chief Executive Officer Dr. Michael Clayman. And he is joined by Dan Deardorf, Senior Vice President of Commercial Operations.

Before we begin, I need to remind you that we will be making forward-looking statements during this teleconference that include commercial, financial, clinical, and regulatory projections. Statements relating to future financial or business performance, conditions or strategies and other business matters, including expectations regarding net sales, operating expenses, cash utilization, clinical, regulatory and commercial developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.

Flexion cautions that these forward-looking statements

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.